Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Galapagos soars on $4-6 billion hopes for new drug

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Galapagos to an all-time high as analysts forecast multibillion-dollar sales.

Read More »

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

Read More »

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

EpicGenetics and Massachusetts General Hospital to Launch Fibromyalgia Clinical Trial

EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.

Read More »

Merck KGaA, Pfizer’s immuno-drug shown to alleviate kidney cancer

Merck KGaA said the immunotherapy Bavencio, jointly developed with Pfizer Inc., delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.

Read More »

One in three U.S. teens text while driving, survey shows

One in three teen drivers in the U.S. text while driving, new survey data suggests, and the number may be higher in states where teens start driving at younger ages.

Read More »

Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz and Tremfya in Patients with Moderate-to-Severe Plaque Psoriasis

Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.

Read More »

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Read More »

Tezepelumab Granted Breakthrough Therapy By FDA

Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom